Ontology highlight
ABSTRACT: Background
Circulating tumor cell (CTC) count have prognostic role for metastatic breast cancer (MBC). No clear biomarkers can guide selection of chemotherapy (CT) or endocrine therapy (ET) in 1st-line setting of hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR+HER2-) MBC. The present study investigated the prognostic role CT or ET according to the CTC count in HR+HER2- MBC.Methods
We consecutively collected the data of 53 HR+HER2- MBC patients who received 1st-line CT or ET, who had CTC count detected by our peptide-based nanomagnetic CTC isolation system (Pep@MNPs) from January 2014 to December 2015. The clinicopathological characteristics according the CTC count and 1st-l
SUBMITTER: Shao B
PROVIDER: S-EPMC9469166 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature